Plasma D‐dimer and interleukin‐6 are associated with treatment response and progression‐free survival in advanced NSCLC patients on anti‐PD‐1 therapy
Abstract Background/Aims Response to therapy after using immune checkpoint inhibitors (ICIs) is unpredictable due to significant interindividual variation in efficacy among advanced non‐small cell lung cancer (NSCLC) patients. The current study centered on the identification of perivascular blood bi...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2023-08-01
|
| Серія: | Cancer Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1002/cam4.6222 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|